| ABT |
Report |
2Q26 adjusted EPS |
BEAT |
pred ~$1.31 vs. cons $1.28 |
MEDIUM |
| ABT |
Report |
2Q26 comparable sales growth |
IN-LINE |
pred ~10.0% vs. cons 9.85% |
MEDIUM |
| ABT |
Report |
2Q26 Diabetes Care / CGM comparable sales growth |
IN-LINE |
pred ~10.5% vs. cons 10.0% |
MEDIUM |
| ABT |
Guide |
FY26 comparable sales-growth outlook |
UNCHANGED |
guide ~7.0% midpoint vs. cons 7.0% (FY26) |
HIGH |
| ABT |
Guide |
FY26 adjusted EPS outlook |
UNCHANGED |
guide ~$5.48 midpoint vs. cons $5.50 (FY26) |
MEDIUM |
| ABT |
Guide |
Exact Sciences acquisition-related adjusted-EPS dilution |
UNCHANGED |
guide ~$0.20 dilution vs. cons $0.20 dilution (FY26) |
HIGH |
| ABT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| ABT |
Return |
5-day cumulative residual |
+1.0% (FADE) |
~+2.5% day-1 residual vs. ~+1.0% five-day residual: a modest EPS beat and restored double-digit CGM growth should support the initial reaction, but unchanged FY26 EPS and sales outlook leaves the second-half acceleration embedded in out-period math rather than creating a material estimate-revision catalyst. |
MEDIUM |